Taxus data previewed
This article was originally published in The Gray Sheet
Executive Summary
TAXUS IV reports major adverse event rate of 10.6% after 12 months compared with 19.8% for control, and sustained benefits in diabetics, Boston Scientific says. The paclitaxel-eluting stent will go before FDA panel review Nov. 20 [Editor's note: For information on a live broadcast or videotape of the FDA Circulatory System Devices Panel go to FDAAdvisoryCommittee.com, or contact Julie Robenson at 301-664-7203]...
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.